Method of reducing the undesirable gastrointestinal effects of p

Details Method of reducing the undesirable gastrointestinal effects of p Method of reducing the undesirable gastrointestinal effects of p

1976-08-09

1977-12-06

Rosen, Sam

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

424273P, 424274, 424305, 424317, A61K 3161, A61K 31215, A61K 3119

Patent

active

040617424

ABSTRACT:
There is disclosed concomitant systemic administration of certain prostaglandins of the PGE-type and PGA-type, for example, 16,16-dimethyl-PGE.sub.2 of 16,16-dimethyl-PGA.sub.2, and a prostaglandin synthetase inhibitor, for example, indomethacin, aspirin, or phenylbutazone, to mammals, including humans. Thereby the undesirable gastrointestinal effects of the synthetase inhibitor are reduced.

REFERENCES:
patent: 3927213 (1976-02-01), Lippmann

Affiliated with

Also associated with

Rating

Method of reducing the undesirable gastrointestinal effects of p does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of reducing the undesirable gastrointestinal effects of p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of reducing the undesirable gastrointestinal effects of p will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1551050